Pharmacology, Toxicology and Pharmaceutical Science
Inflammatory Arthritis
100%
Insulin Analog
100%
Multiple Myeloma
100%
Rheumatoid Arthritis
100%
Biosimilar Agent
100%
Overall Survival
100%
Etanercept
100%
Non Insulin Dependent Diabetes Mellitus
100%
Observational Study
100%
Progression Free Survival
66%
Hemoglobin A1c
50%
Protamine
33%
Hypoglycemia
33%
Insulin Glargine
33%
Nocturnal Hypoglycemia
33%
Insulin Lispro
33%
Randomized Controlled Trial
33%
Biological Product
7%
Disease Exacerbation
7%
Medicine and Dentistry
Systemic Vasculitis
100%
Multiple Myeloma
100%
Meta-Regression
100%
Stem Cell Transplant
80%
Insulin Lispro
66%
Overall Survival
60%
Progression Free Survival
40%
Lung
33%
Vascular Occlusion
33%
Cell Death
33%
Vascular Bundle
33%
Congestive Heart Failure
33%
Immunosuppressive Treatment
33%
Aneurysm
33%
Myocarditis
33%
Vasculitis
33%
Valvular Heart Disease
33%
Pulmonary Vasculitis
33%
Heart Muscle Ischemia
33%
Pericarditis
33%
Cellular Infiltration
33%
Pulmonary Hypertension
33%
Cardiovascular System
33%
Inflammatory Cell
33%
Coronary Vessel
33%
Randomized Controlled Trial
20%
Immunology and Microbiology
Connective Tissue
100%
Autoimmune Rheumatic Disease
100%
Immunoassay
100%
Protein Expression
66%
Ro Antibody
33%
Mixed Connective Tissue Disease
18%
Systemic Lupus Erythematosus
9%
Systemic Scleroderma
9%
Myositis
9%
Overlap Syndrome
9%